Abstract | INTRODUCTION: PATIENTS AND METHODS: We retrospectively analyzed the safety and efficacy of ambrisentan in patients with PoPH in four German university hospitals. RESULTS: 14 patients with moderate to severe PoPH were included. The median follow-up was 16 months (IQR, 12 - 21). 6 minute walk tests after 6 and 12 months improved from 376 meters (IQR, 207 - 440) at baseline to 415 meters (IQR, 393 - 475; p = 0.011) and 413 meters (IQR, 362 - 473, p = 0.005), respectively. WHO- functional class after 1 year of therapy with ambrisentan also improved significantly (p = 0.014). No significant changes in blood gas analysis and liver function tests ( aspartate aminotransferase, alanine aminotransferase, total bilirubin, and international normalized ratio) during therapy with ambrisentan were detectable. CONCLUSIONS: The present study demonstrates significant improvement of exercise capacity and clinical symptoms without relevant safety concerns during ambrisentan treatment in patients with PoPH.
|
Authors | M Halank, L Knudsen, H-J Seyfarth, R Ewert, B Wiedemann, M Kolditz, G Höffken, M M Hoeper |
Journal | Zeitschrift fur Gastroenterologie
(Z Gastroenterol)
Vol. 49
Issue 9
Pg. 1258-62
(Sep 2011)
ISSN: 1439-7803 [Electronic] Germany |
PMID | 21887662
(Publication Type: Journal Article)
|
Copyright | © Georg Thieme Verlag KG Stuttgart · New York. |
Chemical References |
- Antihypertensive Agents
- Phenylpropionates
- Pyridazines
- ambrisentan
|
Topics |
- Antihypertensive Agents
(pharmacology, therapeutic use)
- Dose-Response Relationship, Drug
- Exercise
- Exercise Test
- Follow-Up Studies
- Humans
- Hypertension, Pulmonary
(drug therapy, physiopathology)
- Phenylpropionates
(pharmacology, therapeutic use)
- Pyridazines
(pharmacology, therapeutic use)
- Retrospective Studies
- Treatment Outcome
|